DXB 1.30% 7.6¢ dimerix limited

Dimerix is GO, page-2

  1. 830 Posts.
    lightbulb Created with Sketch. 169
    Just a few numbers from presentations:

    FSGS drug market is estimated at $1B ANNUALLY
    Diabetic Nephropathy drug market estimated at $1.5B ANNUALLY in the US (I think $2.5B annually in the world)

    If we received a T/O offer of $700m, that would equate to approx. $5 per share

    The potential here is staggering.

    We also have Doctors on our FSGS medical advisory board that are board members of Big Pharma companies AstraZeneca and others, as well as our own directors James Williams and Hugh Alsop having fantastic success taking other drugs to commercialisation. We have fantastic phase 2A data, a reformulated 2 dose a day drug, fully cashed up for rest of phase 2 clinical trials, a small tight register. Our board have gone about this strategically, and done it fantastically well. We are very well positioned and with a market cap of <$20m, this company is the gift of a lifetime!! I would say any takeover would be much higher than the $500m VLA received and IMO, it is a not a question of if, but a question of when.
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
7.6¢
Change
-0.001(1.30%)
Mkt cap ! $12.06M
Open High Low Value Volume
7.7¢ 7.7¢ 7.6¢ $35.82K 470.7K

Buyers (Bids)

No. Vol. Price($)
3 220000 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 6379 1
View Market Depth
Last update - 16.10pm 21/05/2019 (20 minute delay) ?
(live)
Last
7.6¢
  Change
-0.001 ( 1.30 %)
Open High Low Volume
7.6¢ 7.7¢ 7.6¢ 51935
Last updated 14.50pm 21/05/2019 (live) ?
DXB (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.